Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune-targeted Therapy Combined With Lysogenic HSV Virus for Neoadjuvant Treatment of Resectable HNSCC
NCT06741982Phase 1Withdrawn
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in head and neck squamous cell carcinoma (HNSCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Incidence of dose-limiting toxicity. Planned start Dec 2024; status: withdrawn.
02
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06741982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06741982.